- Home
- / Albireo Pharma
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Albireo Pharma financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$44.1
2023-03-02
Market Capitalization
$915.9 M
2023-03-02
Revenue
$40.6 M
FY, 2021
CreditSafe Score
?
Score changed on Jun 06, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.7M | 9.6M | 8.3M | 40.6M | |||||||
| Cost of goods sold | 1.4M | ||||||||||
| Gross profit | 39.2M | ||||||||||
| General and administrative expense | 9.3M | 6.8M | 6.8M | 5.6M | 6.4M | 10.3M | 15.2M | 18.1M | 23.0M | 42.4M | 69.6M |
| Operating expense total | 23.2M | 19.4M | 21.1M | 19.8M | 19.8M | 14.0M | 28.2M | 49.8M | 68.5M | 119.2M | 162.7M |
| EBIT | (24.6M) | (37.9M) | (61.1M) | (96.3M) | (123.5M) | ||||||
| EBIT margin, % | -297.4% | -634.2% | -1158.8% | ||||||||
| Interest income | 60.0K | 80.0K | |||||||||
| Interest expense | 40.0K | 4.8M | 5.3M | 11.4M | (13.9M) | ||||||
| Pre tax profit | (10.6M) | (20.7M) | (19.3M) | (14.1M) | (18.7M) | (13.7M) | (24.2M) | (46.1M) | (62.7M) | (107.6M) | (34.0M) |
| Income tax expense | 41.0K | 18.0K | 15.0K | 26.0K | 29.0K | 52.0K | 212.0K | 20.0K | |||
| Net Income | (10.6M) | (20.7M) | (19.3M) | (14.1M) | (18.7M) | (13.8M) | (24.4M) | (46.1M) | (62.7M) | (107.6M) | (34.0M) |